Two Mothers, Two Realities

In a small apartment in Rustavi, an 11-year-old boy named Rasul still dreams of football. He cannot run much anymore, so he asks to play goalkeeper. His mother watches him fall on the pavement, again and again, pretending not to notice the stares from strangers. Every step matters now. Every month matters even more.

Thousands of kilometers away, another mother watches her son after receiving advanced treatment for Duchenne Muscular Dystrophy (DMD). She sees him climbing stairs more easily. Standing longer. Smiling more. She still fears the future, but hope has entered the room again.

These two women live in different realities.

And increasingly, the dividing line between them is not only science. It is access, healthcare systems, affordability, and information.

A disease that steals childhood

Duchenne Muscular Dystrophy is one of the cruelest genetic diseases known to medicine. Affecting mostly boys, it progressively destroys muscle tissue until children lose the ability to walk, then struggle to breathe, and eventually suffer heart failure.

Most boys become wheelchair users around the ages of 11 or 12. Many do not survive beyond early adulthood.

For decades, families had little more than steroids and physiotherapy. Treatments could slow the disease slightly, but not fundamentally change its direction.

Now, science is finally beginning to fight back.

New therapeutic approaches are beginning to change the conversation around Duchenne. While not curative, some treatments may help slow aspects of disease progression for certain patients, though outcomes and eligibility vary.

For many families, preserving time and function can feel deeply meaningful.

The mothers sleeping outside government buildings

In Tbilisi, mothers of children with DMD have spent nights outside government offices wrapped in blankets, sleeping on benches after police reportedly refused to allow tents during protests.

Many of them are no longer employees, professionals, or independent adults in the ordinary sense. They have become full-time caregivers, physiotherapists, advocates, nurses, and researchers because many families feel compelled to advocate directly for access and support.

Our children’s birthdays never make us happy.

Every year means further muscle deterioration. Another described how her son now asks when the medicine will finally arrive because he is “tired.”

These families are not demanding miracles. They know the drugs are imperfect. They know there are risks. They know some therapies remain controversial and staggeringly expensive.

But they also know what happens without treatment.

Without intervention, Duchenne typically follows a progressive course.

The other side of the argument

The Georgian government argues that caution is necessary. Officials have pointed to unresolved scientific questions, regulatory concerns, and serious safety risks associated with some advanced therapies.

And those concerns are not imaginary.

Regulatory agencies continue to evaluate both potential benefits and risks as evidence evolves.

Gene therapies can cost millions of dollars per patient. Long-term outcomes are still being studied. Regulators worldwide continue debating effectiveness standards and risk thresholds.

Those are legitimate issues.

But what transforms a medical debate into a moral crisis is what happened next.

When information becomes a weapon

According to an investigation by Myth Detector cited by JAMnews, dozens of allegedly fake social media accounts amplified messaging attacking DMD medications and discrediting parents advocating for access to treatment in Georgia.

The investigation claimed coordinated accounts boosted narratives portraying treatments as unsafe, exaggerated, or politically manipulated. Investigations by independent media outlets raised concerns about how public narratives around treatment access may shape perception and trust among affected families.

This is where misinformation stops being abstract.

Because every delay in Duchenne treatment has a physical cost.

In a progressive condition such as Duchenne, changes in mobility and function can occur over time, making timing especially meaningful to many families.

A lung function score lost today may never return.

A boy who misses the eligibility window for a therapy may lose that opportunity forever.

Online campaigns and political narratives may feel intangible to outsiders, but for families living with Duchenne, they can shape policy decisions that determine whether a child receives treatment in time.

And time, in Duchenne, is not a slogan.

For many families, time can shape mobility, independence, and quality of life.

Two mothers, two futures

One mother spends nights researching clinical trials and side effects because she has access to specialists, multidisciplinary teams, and treatment pathways.

The other spends nights protesting in the cold, praying her child remains eligible long enough for decisions about access to be made.

One mother worries whether a treatment will provide five extra years of mobility.

The other worries whether her son will lose the ability to stand before the next government meeting.

This is the hidden cruelty of unequal healthcare systems. They create parallel universes for families facing the same disease.

In one reality, access pathways evolve quickly. In another, families face uncertainty.

Beyond Georgia

The struggle unfolding in Georgia reflects a global tension that is becoming increasingly common in modern medicine.

Advanced therapies are arriving faster than healthcare systems can adapt to them. Governments fear unsustainable costs. Regulators fear approving therapies too quickly. Advanced therapies often involve substantial costs, creating difficult questions around sustainability and access. Families become activists because nobody else is fighting hard enough for their children.

But the Georgian case also exposes something darker: how public distrust can be cultivated around vulnerable patients and desperate parents.

Distinguishing between healthy scientific scrutiny and harmful misinformation can be difficult, particularly in emotionally charged healthcare debates.

Sometimes caution is necessary. Science requires scrutiny.

But when fear-based narratives drown out human reality, society risks forgetting who ultimately pays the price.

Ultimately, families and children living with Duchenne experience the consequences of delayed decisions, uncertainty, and unequal access most directly.

And their mothers carry that burden every single day.